Press Releases

Press Releases
Date Title and Summary View
Jan 26, 2017 Net Product Sales $2.98B in Q4:16; Increased 17% Y/Y Net Product Sales $11.18B in 2016; Increased 22% Y/Y 2017 Guidance for Net Product Sales and Diluted EPS SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported opera...
PDF
Add to Briefcase
Jan 26, 2017 Expands pipeline of potential next-generation medicines for the treatment of patients with autoimmune disorders SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. ("Delinia"), a privately held biotechnology company developing novel therape...
Jan 9, 2017 Preliminary 2016 Unaudited Financial Results Including Net Product Sales and Diluted EPS Raising 2017 Guidance for Total Revenue and Diluted EPS Reaffirming 2020 Total Revenue and Adjusted Diluted EPS Financial Targets SUMMIT...
PDF
Add to Briefcase
Jan 4, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.m. ET to discuss fourth quarter and full-year 2016 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgen...
Jan 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2016 financial results and an updated financial outlook. The presentation and ...
Dec 22, 2016 First-in-class oral treatment for psoriatic arthritis made available via the National Health Service (NHS) STOCKLEY PARK, England--(BUSINESS WIRE)-- Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) ...
Dec 20, 2016 -- Early results recently announced with JCAR017 in non-Hodgkin lymphoma and pediatric acute lymphoblastic leukemia -- Pivotal DLBCL trial expected to begin in 2017 SEATTLE & SUMMIT, N.J.--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO) and Celgene Corporation (NASDA...
Dec 20, 2016 The first oral treatment in 25 years for patients in Japan with these diseases SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA® (apremilast), Celgene's oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full ma...
Dec 7, 2016 Phase II tnAcity Trial found a significantly longer Progression Free Survival with ABRAXANE + carboplatin compared to ABRAXANE + gemcitabine or carboplatin + gemcitabine regimens SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the results of it...
Dec 6, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG), today announced results from two studies (Abstracts #1143, LBA-1) evaluating the investigational use of REVLIMID® (lenalidomide) maintenance therapy in patients with multiple myeloma. These studies were presented at the 58th American ...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase